Interferon signal transduction of biphenyl dimethyl dicarboxylate/ amantadine and anti-HBV activity in HepG2 2.2.15

Archives of Pharmacal Research

Volumn 29, Issue 5, 2006, Pages 405-411

  Seong, Soo Joo ^a   Tae, Joon Won ^a   Min, Jung Kim ^a   Kwang, Woo Hwang ^a   Do, Ik Lee ^a  

^a Chung Ang University   (South Korea)

Author keywords

6 16; Amantadine; Chronic hepatitis B; DDB; Interferon alpha; ISG12; Jak Stat

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 7,7' DIMETHOXY (4,4' BI 1,3 BENZODIOXOLE) 5,5' DICARBOXYLIC ACID DIMETHYL ESTER; 7,7'-DIMETHOXY-(4,4'-BI-1,3-BENZODIOXOLE)-5,5'-DICARBOXYLIC ACID DIMETHYL ESTER; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; IFI27 PROTEIN, HUMAN; IFI6 PROTEIN, HUMAN; INTERFERON RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; VIRUS RNA;

ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER CELL; METABOLISM; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; VIROLOGY; VIRUS REPLICATION;

AMANTADINE; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; MEMBRANE PROTEINS; MITOCHONDRIAL PROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RNA, MESSENGER; RNA, VIRAL; SIGNAL TRANSDUCTION; TIME FACTORS; VIRUS REPLICATION;

EID: 33744932690     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02968591     Document Type: Article

References (21)

1. Acs, G., Sells, M. A., Purcell, R. H., Price, P., Engle, R., Shapiro, M., and Popper, H., Hepatitis B virus produced by transfected HepG2 cells causes hepatitis in chimpanzees. Proc. Natl. Acad. U.S.A., 84, 4641-4644 (1987).
2. Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., and Cheng, Y. C., Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U.S.A., 88, 8495-8499 (1991).
3. Fernandez, M., Quiroga, J. A., and Carreno, V., Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J. Gen. Virol., 84, 2073-2083 (2003).
4. Gao, M., Zhang, J., and Liu, G., Effect of diphenyl dimethyl bicarboxylate on concanavalin A-induced liver injury. Liver Int., 25, 904-912 (2005).
5. Gjermandersen, I. M., Justesen, J., and Martenen, P. M., The interferon induced gene ISG12 is regulated by various cytokines as the gene 6-16 in human cell line. Cytokine, 12, 233-238 (2000).
6. Guidotti, L. G., Guilhot, S., and Chisari, F. V., Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and - independent pathways. J. Virol., 68, 1265-1270 (1994).
7. Hershey, J. H., Schowalter, L., and Baily, S., Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings. Am. J. Med., 118, 100S-108S (2005).
8. Jacobs, B. L. and Langland, J. O., When two strands are better than one: the mediators and modulators of the cellular responses to double stranded RNA. Virology, 219, 339-349 (1996).
9. Joo, S. S. and Lee, D. I., The potential anti-HBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in HepG2 2.2.15 cells. Arch. Pharm. Res., 28, 451-457 (2005).
10. Lee, W. M., Hepatitis B virus infection. N. Engl. J. Med., 337, 1733-1745 (1997).
11. Leung, N., Treatment of chronic hepatitis B: case selection and duration of therapy. J. Gastroen. Hepatol., 17, 409-414 (2002).
12. Liaw, Y. F., Leung, N. W., Chang, T. T., Guan, R., Tai, D. I., Ng, K. Y., Chien, R. N., Dent, J., Roman, L., Edmundson, S., and Lai, C. L., Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 119, 172-180 (2000).
13. Lim, Y. S. and Suh, D. J., Current antiviral therapy for chronic hepatitis B. J. Korean Med. Sci., 19, 489-494 (2004).
14. Lok, A. S., Chronic hepatitis B. N. Engl. J. Med., 346, 1682-1683 (2002).
15. Malik, A. H. and Lee, W. M., Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med., 132, 723-731 (2000).
16. Morita, K., Tanaka, K., Saito, S., Kitamura, T., Kondo, T., Sakaguchi, T., Morimoto, M., and Sekihara. H., Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J. Clin. Gastroenterol., 26, 135-140 (1998).
17. Nassal, M. and Schaller, H., Hepatitis B virus replication - an update. J. Viral. Hep., 3, 217-226 (1996).
18. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P., Estimating the world cancer burden: Globocan 2000. Int. J. Cancer., 94, 153-156 (2001).
19. Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hrsch, K., Wright, T., Gutfreund, K., Lamy, P., and Murray, A., Adefovir dipivoxil for the treatment of lamivudine-resistance hepatitis B mutants. Hepatology, 32, 129-134 (2000).
20. Samuel, C. E., Antiviral actions of interferons. Clin. Microbiol. Rev., 14, 778-809 (2001).
21. Younger, H. M., Bathgate, A. J., and Hayes, P. C., Review article: nucleoside analogues for the treatment of chronic hepatitis B. Aliment. Pharmacol. Ther., 20, 1211-1230 (2004).